Chronic pain is prevalent among U.S. military personnel and often accompanied by comorbid behavioral health disorders and other medical conditions that further complicate its management. According to the Centers for Disease Control and Prevention, the prevalence of chronic pain among active-duty Service members is 1.5 to 2 times higher than the 20% of American adults who live with chronic pain. Recent report findings determined that Service members make up a large population within the Military Health Systems (MHS), and that this population is disproportionately affected by lost duty days, early retirement, loss of readiness, and increased burden to the MHS. To date, the Department of Defense (DOD) and MHS have emphasized multimodal, multidisciplinary, stepped treatment for chronic pain that prioritizes nonpharmacologic therapies and non- opioid pain medications. Though the DOD and MHS have invested in several pain treatment types, our level of understanding needs to better distinguish between acute and chronic pain and identify risk factors and mechanisms responsible for the chronification of pain, as it is the chronic pain which compromises functioning and readiness to a greater degree across the force. The novel information generated by this study will enhance our understanding of how ankle fracture elicits pathological risk factors for bone fracture associated neuropathic pain (BFNP), which ultimately impairs health-related quality of life. Due to the high prevalence of ankle fractures and the subsequent risk of developing chronic pain after ankle fracture, we will utilize this patient population to provide the preliminary evidence on whether bone fracture and subsequent BFNP phenotypes are reflected in specific genetic profiles and activated states of immune cells.
Competing Interest StatementThe authors have declared no competing interest.
Clinical TrialNCT06420141 Recruiting The Prevalence of Neuropathic Pain Pathophysiology Associated With Ankle Fracture
Clinical Protocolshttps://clinicaltrials.gov/study/NCT06420141?locStr=Indianapolis
Funding StatementYes
Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Indiana University School of Medicine IRB IRB: #19914 Form of consent obtained (written/oral)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Comments (0)